Professional
Added to YB: 2024-10-23
Pitch date: 2024-09-30
NVO [bullish]
Novo Nordisk A/S
-58.4%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 116.46
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
growth
Show full summary:
Baron International Growth Fund Portfolio Holding: Novo Nordisk A/S
NVO: Leader in GLP-1 drugs for diabetes/obesity. Ozempic/Wegovy drive 15% weight loss, improve cardiovascular outcomes. Monlunabant setback irrelevant to thesis. Bullish on CagriSema (Ozempic + amylin agonist) and amycretin (dual GLP1/amylin agonist) as best-in-class GLP-1 drugs.
Read full article (1 min)